SoFi's stock had a historic drop earlier this week. What if it was misguided?
By Emily Bary
A Mizuho analyst thinks Wall Street was too downbeat on the company's capital raise, which he views positively
SoFi Technologies Inc.'s bid to raise capital sparked a record one-day selloff in its shares earlier this week. But what if Wall Street was misunderstanding the impact of that financial move?
Mizuho analyst Dan Dolev seems to think that's the case. Despite sharp pressure on the stock at the time of the announcement Tuesday, he thinks shares will move higher "once investors understand the many positives" associated with SoFi's (SOFI) convertible-note offering and equity exchange.
See also: Here's why SoFi's stock just logged its worst day on record
For one, Dolev calculates that SoFi's $600 million equity exchange could deliver a 10% increase to the company's tangible book value per share and boost its capital ratio by upwards of 200 basis points. And at the same time, he doesn't expect the transaction will dilute earnings per share this year in any "meaningful" way.
Additionally, Dolev commented that the company's roughly $750 million convertible-debt offering could save SoFi more than $60 million in annual interest expense, such that the company could pay back its roughly $90 million in capped-call costs within a year and a half.
He further noted that the capped call means that shares won't be diluted unless SoFi shares double to $14.54 a share from the $7.27 deal-closing price.
SoFi shares dropped 15.3% in Tuesday's session after the company announced the capital raise, logging their largest single-day percentage decline in the process. But the stock is up 3.6% in Friday trading, which would make for its third session in a row of gains.
Dolev, for his part, has a buy rating and $12 target price on SoFi shares, and he thinks more could join his camp soon. The convertible offering "could help convert bears into bulls," he said.
-Emily Bary
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-08-24 1458ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing